Directory
Luis Brieva Ruiz

Luis Brieva Ruiz

Degree: PhD

973 705 367
lbrieva.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/C-3812-2011

Publications

  • Sancho--Saldaña, A; Gil-Sánchez, A; González-Mingot, C; Peralta, S; Solana, MJ; Torres, P; Juanes, A; Quibus, L; Ruiz, E; Sanpedro, E; Quirant-Sánchez, B; Martínez-Cáceres, E; Tello, CR; Presas-Rodríguez, S; Rubio, SG; Baron, BP; Ramio-Torrenta, L; Sotoca, J; González-Suarez, I; Eichau, S; Prieto-Gonzalez, JM; Quilez, MRB; Sabin-Muñoz, J; Sánchez-López, AJ; Calatayud, GL; Calles, C; Sempere, AP; Garces, M; Carmona, O; Moral, E; Hervas, JV; Blanco, Y; Sola-Valls, N; Lara, NT; Forero, L; Brieva, L

    Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

    Journal of Clinical Medicine 12 -. .

    [doi:10.3390/jcm12237243]

  • Brochet, B; Solari, A; Lechner-Scott, J; Piehl, F; Langdon, D; Hupperts, R; Selmaj, K; Patti, F; Brieva, L; Maida, EM; Alexandri, N; Smyk, A; Nolting, A; Keller, B; Montalban, X; Havrdova, EK

    Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study

    MULTIPLE SCLEROSIS JOURNAL 29 1808-1818. .

    [doi:10.1177/13524585231205962]

  • Mingot, CG; Lasaosa, SS; Campas, LC; Canaval, LC; Sánchez, AG; Ruiz, LB; Alonso, MCM; Moncusi, SP; Marsal, JV; Carner, SC; García, FP

    Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot study

    SCIENTIFIC REPORTS 13 19416-19416. .

    [doi:10.1038/s41598-023-44522-8]

  • Koch, MW; Moral, E; Brieva, L; Mostert, J; Strijbis, EM; Comtois, J; Repovic, P; Bowen, JD; Wolinsky, JS; Lublin, FD; Cutter, G

    Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset

    MULTIPLE SCLEROSIS JOURNAL 29 1776-1785. .

    [doi:10.1177/13524585231202320]

  • González-Mingot, C; Miana-Mena, FJ; Iñarrea, PJ; Iñiguez, C; Capablo, JL; Osta, R; Gil-Sánchez, A; Brieva, L; Larrodé, P

    Mitochondrial Aconitase Enzymatic Activity: A Potential Long-Term Survival Biomarker in the Blood of ALS Patients

    Journal of Clinical Medicine 12 -. .

    [doi:10.3390/jcm12103560]

  • Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L

    A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.

    JOURNAL OF NEUROLOGY 270 1-12. .

    [doi:10.1007/s00415-023-11575-8]

  • Gil-Sanchez A; Canudes M; Valcheva P; Nogueras L; González-Mingot C; Hervás JV; Peralta S; Solana MJ; Brieva L

    Effects of vortioxetine on cognition and fatigue in patients with multiple sclerosis and depression: a case series study.

    CNS & Neurological Disorders-Drug Targets 23 395-401. .

    [doi:10.2174/1871527322666230321093133]

  • Lleixà C; Caballero-Ávila M; Pascual-Goñi E; Martín-Aguilar L; Vidal N; Tejada C; Valdés-Hevia E; Zárate E; Vesperinas A; Collet R; Franco-Leyva T; Martínez-Martínez L; Moga E; Cortés-Vicente E; Rojas-García R; Gómez-Anson B; Gil A; González-Mingot C; Brieva L; Martínez-Yélamos S; Querol L

    Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis.

    Brain Communications 5 -. .

    [doi:10.1093/braincomms/fcad109]

  • Monreal, E; Fernandez-Velasco, JI; Garcia-Sanchez, MI; Sainz de la Maza S; Llufriu, S; Alvarez-Lafuente, R; Casanova, B; Comabella, M; Ramio-Torrenta, L; Martinez-Rodriguez, JE; Brieva, L; Saiz, A; Eichau, S; Cabrera-Maqueda, JM; Villarrubia, N; Espiño M; Perez-Miralles, F; Montalban, X; Tintore, M; Quiroga-Varela, A; Dominguez-Mozo, MI; Rodriguez-Jorge, F; Chico-Garcia, JL; Lourido, D; Alvarez-Cermeno, JC; Masjuan, J; Costa-Frossard, L; Villar, LM

    Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.

    JAMA Neurology 80 397-403. .

    [doi:10.1001/jamaneurol.2023.0010]

  • de la Maza, SS; Gómez-Ballesteros, R; Borges, M; Martín-Martínez, J; Sotoca, J; Alonso, A; Caminero, AB; Borrega, L; Sánchez-Menoyo, JL; Barrero-Hernández, FJ; Calles, C; Brieva, L; Blasco-Quílez, MR; García-Soto, JD; del Campo-Amigo, M; Navarro-Cantó, L; Agüera, E; Garcés-Redondo, M; Carmona, O; Gabaldón-Torres, L; Forero, L; Hervàs, M; Medrano, N; Maurino, J; Castillo-Triviño, T

    Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach

    Multiple Sclerosis Journal-Experimental Translational And Clinical 9 -. .

    [doi:10.1177/20552173231169475]

  • Saposnik, Gustavo; Andhavarapu, Sanketh; Sainz de la Maza S; Castillo-Trivino, Tamara; Borges, Monica; Baron, Beatriz Pardinas; Sotoca, Javier; Alonso, Ana; Caminero, Ana B.; Borrega, Laura; Sanchez-Menoyo, Jose L.; Barrero-Hernandez, Francisco J.; Calles, Carmen; Brieva, Luis; Blasco, Maria R.; -Soto, Julio Dotor Garcia; del Campo-Amigo, Maria; Navarro-Canto, Laura; Agüera E; Garces, Moises; Carmona, Olga; Gabaldon -Torres, Laura; Forero, Lucia; Hervas, Mariona; Garcia-Arcelay, Elena; Terzaghi, Maria; Gomez-Ballesteros, Rocio; Maurino, Jorge

    Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis.

    Multiple Sclerosis and Related Disorders 68 104138-104138. .

    [doi:10.1016/j.msard.2022.104138]

  • Meca-Lallana, J E; Fernandez-Prada, M; Garcia Vazquez, E; Moreno Guillen, S; Otero Romero, S; Rus Hidalgo, M; Villar Guimerans, L M; Eichau Madueño S; Fernandez Fernandez, O; Izquierdo Ayuso, G; Álvarez Cermeño JC; Arnal Garcia, C; Arroyo Gonzalez, R; Brieva Ruiz, L; Calles Hernandez, C; Garcia Merino, A; Gonzalez Plata, M; Hernandez Perez, M A; Moral Torres, E; Olascoaga Urtaza, J; Oliva-Nacarino, P; Oreja-Guevara, C; Ortiz Castillo, R; Oterino, A; Prieto Gonzalez, J M; Ramio-Torrenta, L; Rodriguez-Antiguedad, A; Saiz, A; Tintore, M; Montalban Gairin, X

    Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.

    Neurologia (barcelona, Spain) 37 615-630. .

    [doi:10.1016/j.nrleng.2019.11.001]

Projects

  • EMCOVID-19: Esclerosis Múltiple y COVID-19
  • "Registro de pacientes con esclerosis múltiple (EM) tratados con Natalizumab en España"
  • UTILIDAD DE LA REALIZACION DE SECUENCIAS DE DIFUSION Y LA DETERMINACION DE BIOMARCADORES EN EL PRONOSTICO DE LOS PACIENTES CON UN ATAQUE ISQUEMICO TRANSITORIO